+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus



Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus



Annals of Translational Medicine 6(13): 259



Esophageal adenocarcinoma (EAC) arising on Barrett esophagus (BE) has become the most frequent type of esophageal malignancy in the Western world. BE is a frequent condition but progression to EAC is rare. Scientific societies publish guidelines in order to improve patients' care. However, there are fields where evidence is lacking or there are many controversies. We aimed to spotlight the most important changes, as well as the points of controversy in the recently published guidelines for BE. For most, a length ≥1 cm of a salmon-pink mucosa extending above the eso-gastric junction is required in order to define BE, accompanied with the presence of intestinal metaplasia (IM) at histology. Screening with endoscopy for the general population is not recommended while there is no proof of the efficacy of screening for targeted high risk populations. New techniques permitting a cytologic examination are under evaluation and may change this strategy. The use of high-resolution endoscopes coupled with a careful inspection of the mucosa are required during surveillance of BE. New studies are necessary in order to clarify the real benefit from the use of advanced techniques, such as virtual chromoendoscopy. Length of non-dysplastic BE plays a role for the interval time determination between endoscopies during surveillance. Indefinite for dysplasia and even more low grade dysplasia (LGD) are debatable issues in the matter of BE. There are compelling data suggesting that a definite LGD, defined as a permanent lesion confirmed by a specialist pathologist in BE, has a more dismal prognosis than previously reported and an ablative intervention may be offered in this case. However, most (75-85%) cases with LGD were downstaged in published studies and it remains unknown if in real life, percentages of downstaging are approaching those of studies or there is an over-treatment of pseudo-LGD. Biomarkers such as p53 immunohistochemistry may aid better identification of patients at higher risk. For high grade dysplasia (HGD) visible lesions should be resected with Endoscopic Mucosal Resection (EMR) while flat lesions ablated, for most, nowadays, with radiofrequency ablation (RFA). Endoscopic submucosal dissection (ESD) has not proved superior compared to EMR in BE. It has to be underlined that most studies leading to the new guidelines for BE are not considered of high quality and new guidelines may emerge in the near future.

(PDF emailed within 1 workday: $29.90)

Accession: 057269507

Download citation: RISBibTeXText

PMID: 30094245


Related references

Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus. Digestive Diseases and Sciences 61(10): 2812-2822, 2016

Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Diseases of the Esophagus 21(8): 685-689, 2008

Surveillance of Barrett's esophagus: a need for guidelines?. Diseases of the Esophagus 10(3): 185-189, 1997

Adherence to Surveillance Guidelines in Nondysplastic Barrett's Esophagus. Journal of Clinical Gastroenterology 52(3): 217-222, 2016

Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. American Journal of Gastroenterology 97(8): 1888-1895, 2002

Screening and surveillance for Barrett esophagus. JAMA Internal Medicine 175(2): 159-160, 2015

How far to go? Screening and surveillance in Barrett's esophagus. American Journal of Managed Care 7(1 Suppl): S19-S26, 2001

Screening and surveillance of Barrett's esophagus. Current Gastroenterology Reports 11(3): 195-201, 2009

Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. American Journal of Gastroenterology 103(3): 788-797, 2008

Screening for and surveillance of Barrett's esophagus is clinically indicated. Digestive Diseases 25(3): 197-202, 2007

Surveillance and screening for Barrett esophagus and adenocarcinoma. Journal of Clinical Gastroenterology 39(4 Suppl 2): S33-S41, 2005

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

Current practice compared with the international guidelines: endoscopic surveillance of Barrett's esophagus. Journal of Evaluation in Clinical Practice 13(5): 789-794, 2007

Adherence to Barrett's Esophagus Surveillance Guidelines: A Systematic Review and Meta-Analysis. Gastroenterology 152(5): S452-S453, 2017

Screening and surveillance in Barrett's esophagus: a call to action. Clinical Gastroenterology and Hepatology 2(10): 861-864, 2004